Experimental studies using OMV in a new platform of SARS-CoV-2 vaccines

References

• Sun P, Lu X, Xu C, Sun W, Pan B. Understanding of COVID-19 based on current evidence. J Med Virol. 2020;92(6):548–51. doi:10.1002/jmv.25722.
   PubMed Web of Science ®Google Scholar
• Harrison AG, Lin T, Wang P. Mechanisms of SARS-CoV-2 transmission and pathogenesis. Trends Immunol. 2020;41(12):1100–15. doi:10.1016/j.it.2020.10.004.
   PubMed Web of Science ®Google Scholar
• Nicola M, Alsafi Z, Sohrabi C, Kerwan A, Al-Jabir A, Iosifidis C, Agha M, Agha R. The socio-economic implications of the coronavirus pandemic (COVID-19): a review. Int J Surg. 2020;78:185–93. doi:10.1016/j.ijsu.2020.04.018.
   PubMed Web of Science ®Google Scholar
• Huang Y, Yang C, Xu X-F, Xu W, Liu S-W. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020;41(9):1141–49. doi:10.1038/s41401-020-0485-4.
   PubMed Web of Science ®Google Scholar
• Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020;5(4):562–69. doi:10.1038/s41564-020-0688-y.
   PubMed Web of Science ®Google Scholar
• Micoli F, MacLennan CA. Outer membrane vesicle vaccines. Semin Immunol. 2020;50:101433. doi:10.1016/j.smim.2020.101433.
   PubMed Web of Science ®Google Scholar
• Sierra GV, Campa HC, Varcacel NM, Garcia IL, Izquierdo PL, Sotolongo PF, Casanueva GV, Rico CO, Rodriguez CR, Terry MH, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 1991;14(2):195–207. discussion 8–10.
   PubMedGoogle Scholar
• Bjune G, Høiby EA, Grønnesby JK, Arnesen Ø, Fredriksen JH, Lindbak A-K, Nøkleby H, Rosenqvist E, Solberg LK, Closs O, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet. 1991;338(8775):1093–96. doi:10.1016/0140-6736(91)91961-S.
   PubMed Web of Science ®Google Scholar
• Arnold R, Galloway Y, McNicholas A, O’Hallahan J. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand. Vaccine. 2011;29(40):7100–06. doi:10.1016/j.vaccine.2011.06.120.
   PubMed Web of Science ®Google Scholar
• O’Ryan M, Stoddard J, Toneatto D, Wassil J, Dull PM. A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program. Drugs. 2014;74(1):15–30. doi:10.1007/s40265-013-0155-7.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Kutateladze TG. Molecular structure analyses suggest strategies to therapeutically target SARS-CoV-2. Nat commun. 2020;11(1):2920.
   PubMed Web of Science ®Google Scholar
• WHO. Draft landscape and tracker of COVID-19 candidate vaccines: WHO; 2021 [accessed 2021 Aug 2]. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
   Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111.
   PubMed Web of Science ®Google Scholar
• Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671–81. doi:10.1016/S0140-6736(21)00234-8.
   PubMed Web of Science ®Google Scholar
• Mancini F, Rossi O, Necchi F, Micoli F. OMV vaccines and the role of TLR agonists in immune response. Int J Mol Sci. 2020;21(12):4416. doi:10.3390/ijms21124416.
   Google Scholar
• Koeberling O, Giuntini S, Seubert A, Granoff DM. Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2. Clin Vaccine Immunol: CVI. 2009;16(2):156–62. doi:10.1128/CVI.00403-08.
   PubMedGoogle Scholar
• Watkins HC, Rappazzo CG, Higgins JS, Sun X, Brock N, Chau A, Misra A, Cannizzo JPB, King MR, Maines TR, et al. Safe recombinant outer membrane vesicles that display M2e elicit heterologous influenza protection. Mol Therapy: J Am Soc Gene Therapy. 2017;25(4):989–1002. doi:10.1016/j.ymthe.2017.01.010.
   PubMed Web of Science ®Google Scholar
• Scaria PV, Rowe CG, Chen BB, Muratova OV, Fischer ER, Barnafo EK, Anderson CF, Zaidi IU, Lambert LE, Lucas BJ, et al. Outer membrane protein complex as a carrier for malaria transmission blocking antigen Pfs230. NPJ Vaccines. 2019;4(1):24. doi:10.1038/s41541-019-0121-9.
   PubMed Web of Science ®Google Scholar
• Grandi A, Tomasi M, Zanella I, Ganfini L, Caproni E, Fantappiè L, Irene C, Frattini L, Isaac SJ, König E, et al. Synergistic protective activity of tumor-specific epitopes engineered in bacterial outer membrane vesicles. Front Oncol. 2017;7:253. doi:10.3389/fonc.2017.00253.
   PubMed Web of Science ®Google Scholar
• FDA. BEXSERO® US prescribing information [internet]. FDA; 2015. [uploaded 2015; cited 2021 Mar 23]. Available from https://www.fda.gov/media/90996/download.
   Google Scholar
• Cook IF. Evidence based route of administration of vaccines. Hum Vaccin. 2008;4(1):67–73. doi:10.4161/hv.4.1.4747.
   PubMed Web of Science ®Google Scholar
• Guy B, Fourage S, Hessler C, Sanchez V, Millet MJ. Effects of the nature of adjuvant and site of parenteral immunization on the serum and mucosal immune responses induced by a nasal boost with a vaccine alone. Clin Diagn Lab Immunol. 1998;5(5):732–36. doi:10.1128/CDLI.5.5.732-736.1998.
   PubMedGoogle Scholar
• Sardiñas G, Reddin K, Pajon R, Gorringe A. Outer membrane vesicles of Neisseria lactamica as a potential mucosal adjuvant. Vaccine. 2006;24(2):206–14. doi:10.1016/j.vaccine.2005.07.064.
   PubMed Web of Science ®Google Scholar
• Micoli F, Alfini R, Di Benedetto R, Necchi F, Schiavo F, Mancini F, Carducci M, Palmieri E, Balocchi C, Gasperini G, et al. GMMA is a versatile platform to design effective multivalent combination vaccines. Vaccine. 2020;8(3):540. doi:10.3390/vaccines8030540.
   Web of Science ®Google Scholar
• Chen DJ, Osterrieder N, Metzger SM, Buckles E, Doody AM, DeLisa MP, Putnam D. Delivery of foreign antigens by engineered outer membrane vesicle vaccines. Proc Natl Acad Sci. 2010;107(7):3099–104. doi:10.1073/pnas.0805532107.
   PubMed Web of Science ®Google Scholar
• Lee DH, Kim S-H, Kang W, Choi YS, Lee S-H, Lee S-R, You S, Lee HK, Chang K-T, Shin E-C, et al. Adjuvant effect of bacterial outer membrane vesicles with penta-acylated lipopolysaccharide on antigen-specific T cell priming. Vaccine. 2011;29(46):8293–301. doi:10.1016/j.vaccine.2011.08.102.
   PubMed Web of Science ®Google Scholar
• Gaspar EB, De Gaspari E. Avidity assay to test functionality of anti-SARS-Cov-2 antibodies. Vaccine. 2021;39(10):1473–75. doi:10.1016/j.vaccine.2021.02.003.
   PubMed Web of Science ®Google Scholar
• Bauer G, Struck F, Schreiner P, Staschik E, Soutschek E, Motz M. The challenge of avidity determination in SARS-CoV-2 serology. J Med Virol. 2021;93(5):3092–3104. doi:10.1002/jmv.26863.
   Google Scholar
• Khatri I, Staal FJT, Van Dongen JJM. Blocking of the high-affinity interaction-synapse between SARS-CoV-2 spike and human ACE2 proteins likely requires multiple high-affinity antibodies: an immune perspective. Front Immunol. 2020;11(2258). doi:10.3389/fimmu.2020.570018.
   PubMedGoogle Scholar
• Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claër L, Quentric P, Fadlallah J, Devilliers H, Ghillani P. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Trans Med. 2021;13(577). doi:10.1126/scitranslmed.abd2223.
   PubMed Web of Science ®Google Scholar
• Watkins HC, Pagan CL, Childs HR, Posada S, Chau A, Rios J, Guarino C, DeLisa MP, Whittaker GR, Putnam D, et al. A single dose and long lasting vaccine against pandemic influenza through the controlled release of a heterospecies tandem M2 sequence embedded within detoxified bacterial outer membrane vesicles. Vaccine. 2017;35(40):5373–80. doi:10.1016/j.vaccine.2017.08.013.
   PubMed Web of Science ®Google Scholar
• Xu K, Zhao Q, Wen X, Wu R, Wen Y, Huang X, Huang Y, Yan Q, Han X, Ma X, et al. A trivalent Apx-fusion protein delivered by E. coli outer membrane vesicles induce protection against Actinobacillus pleuropneumoniae of serotype 1 and 7 challenge in a murine model. PLoS One. 2018;13(1):e0191286. doi:10.1371/journal.pone.0191286. PMID: 29373591; PMCID: PMC5786296
   Google Scholar
• Kim OY, Hong BS, Park K-S, Yoon YJ, Choi SJ, Lee WH, Roh T-Y, Lötvall J, Kim Y-K, Gho YS, et al. Immunization with escherichia coli outer membrane vesicles protects bacteria-induced lethality via Th1 and Th17 cell responses. J Immunol. 2013;190(8):4092–102. doi:10.4049/jimmunol.1200742.
   PubMed Web of Science ®Google Scholar
• Wørzner K, Sheward DJ, Schmidt ST, Hanke L, Zimmermann J, McInerney G, Karlsson Hedestam GB, Murrell B, Christensen D, Pedersen GK, et al. Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice. EBioMed. 2021;63:103197. doi:10.1016/j.ebiom.2020.103197.
   PubMed Web of Science ®Google Scholar
• Veldhoen M. Interleukin 17 is a chief orchestrator of immunity. Nat Immunol. 2017;18(6):612–21. doi:10.1038/ni.3742.
   PubMed Web of Science ®Google Scholar
• Casillo GM, Mansour AA, Raucci F, Saviano A, Mascolo N, Iqbal AJ, Maione F. Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome? Pharmacol Res. 2020;156:104791. doi:10.1016/j.phrs.2020.104791.
   PubMed Web of Science ®Google Scholar
• Ghazavi A, Ganji A, Keshavarzian N, Rabiemajd S, Mosayebi G. Cytokine profile and disease severity in patients with COVID-19. Cytokine. 2021;137:155323. doi:10.1016/j.cyto.2020.155323.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang C, Huang F, Yang Y, Wang F, Yuan J, Zhang Z, Qin Y, Li X, Zhao D, et al. Elevated plasma levels of selective cytokines in COVID-19 patients reflect viral load and lung injury. Natl Sci Rev. 2020;7(6):1003–11. doi:10.1093/nsr/nwaa037.
   PubMed Web of Science ®Google Scholar
• Trzewikoswki De Lima G, Rodrigues TS, Portilho AI, Correa VA, Gaspar EB, De Gaspari E. Immune responses of meningococcal B outer membrane vesicles in middle-aged mice. Pathog Dis. 2020;78(5). doi:10.1093/femspd/ftaa028.
   PubMed Web of Science ®Google Scholar
• De Oliveira Santos FA, Lincopan N, De Gaspari E. Evaluation of intranasal and subcutaneous route of immunization in neonatal mice using DODAB-BF as adjuvant with outer membrane vesicles of Neisseria meningitis B. Immunobiol. 2018;223(12):750–60. doi:10.1016/j.imbio.2018.07.021.
   PubMed Web of Science ®Google Scholar